PCI Biotech Holding ASA (PCIB.OL)

1.6180 -0.0020 (-0.12%) At close: 12:16PM CEST

PCI Biotech Holding ASA

UllernchaussEen 64
Oslo 0379
Norway
47 67 11 54 00
https://www.pcibiotech.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Ronny Skuggedal	CEO & CFO	N/A	N/A	1976
Dr. Anders Hogset Ph.D.	Chief Scientific Officer	N/A	N/A	1954

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in NOK.

Description

PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The company develops anticancer paradigms, including fimaCHEM, a chemotherapeutics for treatment of cancer; fimaVACC, a T-cell induction technology for therapeutic vaccination, which is in pre-clinical study; and fimaNAc, a nucleic acid therapeutics delivery technology, which is in pre-clinical study. It also offers Amphinex, a photosensitiser fimaporfin. The company has collaborative research programs with Olix Pharmaceuticals, Aposense, IMV Immunovaccine, MDimune, eTheRNA, and Immunicum. PCI Biotech Holding ASA was incorporated in 2007 and is based in Oslo, Norway.

Corporate governance

PCI Biotech Holding ASA’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.